The involvement and therapeutic potential of IL-1β in the treatment of type 2 diabetes was recently demonstrated by treatment with the IL-1β receptor antagonist Anakinra, which resulted in improved beta cell secretory function and glycaemia control in human type 2 diabetic patients [11]. Here, IL1B is linked to type 2 diabetes mellitus.